Lebowitz Barry D, Harris Herbert W
National Institute of Mental Health, Bethescla, Mel, USA.
Dialogues Clin Neurosci. 2002 Dec;4(4):325-8. doi: 10.31887/DCNS.2002.4.4/blebowitz.
Mental disorders are among the most disabling of all diseases. Effective well-documented medications have been available for many decades. Yet, limited understanding of the pathophysiology of mental disorders has impeded the development of novel treatments. Drug discovery must move toward a net* mechanism-based paradigm using the tools of contemporary genetic and molecular medicine. At the same time, this new paradigm must be matched by an equivalent effort to modernize established approaches to clinical trials methodology.
精神障碍是所有疾病中致残性最强的疾病之一。有效的、有充分文献记载的药物已经存在了几十年。然而，对精神障碍病理生理学的有限理解阻碍了新疗法的开发。药物研发必须利用当代基因和分子医学工具，朝着基于净*机制的范式发展。与此同时，这种新范式必须辅之以同等力度的努力，以使既定的临床试验方法现代化。
